Goldman Sachs’s China Biologic Products Holdings, Inc. CBPO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-131,060
| Closed | -$15.5M | – | 6838 |
|
|
2021
Q1 | $15.5M | Buy |
131,060
+26,509
| +25% | +$3.14M | ﹤0.01% | 2161 |
|
|
2020
Q4 | $12.3M | Buy |
104,551
+65,254
| +166% | +$7.58M | ﹤0.01% | 2274 |
|
|
2020
Q3 | $4.37M | Sell |
39,297
-28,648
| -42% | -$3.08M | ﹤0.01% | 3012 |
|
|
2020
Q2 | $6.94M | Buy |
67,945
+37,390
| +122% | +$4M | ﹤0.01% | 2546 |
|
|
2020
Q1 | $3.3M | Sell |
30,555
-88,761
| -74% | -$10.2M | ﹤0.01% | 2961 |
|
|
2019
Q4 | $13.9M | Buy |
119,316
+72,376
| +154% | +$8.38M | ﹤0.01% | 2173 |
|
|
2019
Q3 | $5.37M | Sell |
46,940
-6,682
| -12% | -$664K | ﹤0.01% | 2808 |
|
|
2019
Q2 | $5.11M | Sell |
53,622
-80,330
| -60% | -$7.57M | ﹤0.01% | 2827 |
|
|
2019
Q1 | $12.2M | Buy |
133,952
+37,949
| +40% | +$3.11M | ﹤0.01% | 2261 |
|
|
2018
Q4 | $7.29M | Buy |
96,003
+16,027
| +20% | +$1.18M | ﹤0.01% | 2581 |
|
|
2018
Q3 | $6.4M | Sell |
79,976
-32,659
| -29% | -$3.04M | ﹤0.01% | 2791 |
|
|
2018
Q2 | $11.2M | Sell |
112,635
-512,521
| -82% | -$44.3M | ﹤0.01% | 2321 |
|
|
2018
Q1 | $50.6M | Buy |
625,156
+27,757
| +5% | +$2.24M | 0.01% | 1190 |
|
|
2017
Q4 | $47.1M | Buy |
597,399
+534,824
| +855% | +$44.5M | 0.01% | 1330 |
|
|
2017
Q3 | $5.77M | Buy |
62,575
+1,171
| +2% | +$113K | ﹤0.01% | 3009 |
|
|
2017
Q2 | $6.95M | Buy |
61,404
+2,845
| +5% | +$318K | ﹤0.01% | 2794 |
|
|
2017
Q1 | $5.86M | Buy |
58,559
+5,091
| +10% | +$544K | ﹤0.01% | 2809 |
|
|
2016
Q4 | $5.75M | Sell |
53,468
-86,598
| -62% | -$10.1M | ﹤0.01% | 2934 |
|
|
2016
Q3 | $17.4M | Buy |
140,066
+102,804
| +276% | +$12.1M | 0.01% | 2001 |
|
|
2016
Q2 | $3.96M | Buy |
37,262
+14,722
| +65% | +$1.71M | ﹤0.01% | 3049 |
|
|
2016
Q1 | $2.58M | Buy |
22,540
+10,935
| +94% | +$1.28M | ﹤0.01% | 3253 |
|
|
2015
Q4 | $1.65M | Buy |
+11,605
| New | +$1.34M | ﹤0.01% | 3809 |
|
|
2015
Q3 | – | Sell |
-6,035
| Closed | -$695K | – | 7641 |
|
|
2015
Q2 | $695K | Sell |
6,035
-9
| -0.1% | -$946 | ﹤0.01% | 4875 |
|
|
2015
Q1 | $577K | Buy |
+6,044
| New | +$452K | ﹤0.01% | 4986 |
|
Goldman Sachs's CBPO Position: Q2 2021 in Review
Goldman Sachs sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 131,060 shares — an estimated $15.5M sold.
Goldman Sachs first reported a position in CBPO in Q1 2015 and held it in 24 quarters. The position peaked at $50.6M in Q1 2018. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.
- Goldman Sachs reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
- Goldman Sachs sold 131,060 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $15.5M.
- Goldman Sachs first reported a position in China Biologic Products Holdings, Inc. in Q1 2015 and held it in 24 quarters.
- Goldman Sachs's China Biologic Products Holdings, Inc. position peaked at $50.6M in Q1 2018.
- 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.
Based on Goldman Sachs's 13F filing for Q2 2021, filed 13 Aug 2021.